Articles tagged with Sulfonylureas
A recent study published in JAMA Network Open found that glipizide, a commonly used type 2 diabetes medication, is associated with a 13% increase in cardiovascular risk compared to dipeptidyl peptidase-4 (DPP-4) inhibitors. The study analyzed data from nearly 50,000 patients and found that glipizide was linked to higher rates of heart ...
A new study found that the newer generation of effective diabetes medications are not reaching enough patients. The study analyzed data from over 40,000 records and found that only 20% of patients with type 2 diabetes were taking GLP-1 drugs within a year of diagnosis, and less than 15% were taking SGLT2 drugs.
A recent study found that long-term use of sulfonylureas increases the risk of impaired awareness of hypoglycemia in patients with type 2 diabetes. The longer the patient uses sulfonylureas, the higher the risk. Researchers suggest using newer classes of medications to reduce this risk.
Researchers analyzed over 1.5 million patient records to find that metformin and SGLT-2 inhibitors lowered dementia and Alzheimer's disease risks compared to other antidiabetic drugs. The study suggests individualized treatment approaches considering patient-specific factors for optimal diabetes management.
A new observational study published in JAMA sheds light on the use of metformin for patients with Type 2 diabetes and impaired kidney function. The study found that metformin is associated with a 20% decreased risk of major adverse cardiovascular events compared to sulfonylureas.
This observational study compared major cardiovascular events among patients with diabetes and reduced kidney function treated with metformin or a sulfonylurea. The study found that metformin was associated with lower rates of cardiovascular events compared to sulfonylureas.
A Northwestern Medicine study found that sulfonylureas and basal insulin increase the risk of heart attack, stroke, and amputation in patients with Type 2 diabetes. The study suggests a paradigm shift in treatment, recommending newer diabetes medications with more favorable cardiovascular profiles.
A study published in The BMJ found that adding sulfonylurea drugs to metformin for type 2 diabetes is associated with an increased risk of heart attack, all-cause mortality, and severe hypoglycemia. Continuing metformin when introducing sulfonylureas is safer than switching.
A recent study found that infants with diabetes can maintain excellent blood glucose control for up to ten years using sulfonylurea tablets, offering a promising alternative to insulin injections. The treatment has been shown to be safe and effective in children worldwide.
Patients treated first with metformin were less likely to require treatment intensification compared to those who started with sulfonylureas, thiazolidinediones, or DPP-4 inhibitors. Metformin also reduced the need for added insulin and was not associated with increased rates of hypoglycemia or cardiovascular events.
A team of scientists has successfully created a light-sensitive sulfonylurea compound that stimulates insulin release only in response to blue light. This breakthrough could lead to more precise control over blood sugar levels and reduce side effects associated with traditional diabetes treatments.
A retrospective cohort study found patients taking JANUVIA and metformin initiated insulin therapy at a slower rate than those taking a sulfonylurea and metformin. The study suggests that real-world data may provide insight into the effects of different oral treatment regimens on the initiation of insulin use.
A recent study found that adding insulin to metformin for diabetes treatment is associated with an increased risk of nonfatal cardiovascular outcomes and all-cause death. The researchers analyzed data from over 178,000 patients with diabetes who received metformin as their primary treatment.
A post-hoc analysis found that patients with Type 2 diabetes and mild renal impairment treated with JANUVIA achieved similar blood sugar reductions as those treated with sulfonylureas, with significantly fewer hypoglycemia events. Patients taking JANUVIA also experienced weight loss, whereas those on sulfonylureas gained weight.
A large analysis found that three widely used diabetes medications - glipizide, glyburide, and glimepiride - are associated with a greater risk of death compared to metformin. These sulfonylureas were linked to a 50% increased risk of mortality, while glimepiride appeared to be safer in patients with heart disease.
In a post-hoc analysis, elderly patients with type 2 diabetes treated with JANUVIA achieved similar blood sugar reductions as those treated with a sulfonylurea. Notably, patients taking JANUVIA experienced significantly less hypoglycemia, with an incidence of 6.2% compared to 28.2% in patients taking a sulfonylurea.
A new study found that sulfonylurea drugs can restore function and reverse symptoms in infants with neonatal diabetes by blocking potassium channels, potentially avoiding secondary damage to insulin-producing cells. Early treatment with these drugs may circumvent irreversible damage if caught early enough.
Researchers found that sulfonylurea treatment failure is not due to cell death, but rather permanent depolarization of potassium channels. Reversible effects on insulin release were observed in mice treated with slow-release sulfonylureas.
In an animal model, sulfonylureas' effects were found to be reversible after cessation, suggesting beta cells can recover and produce insulin again. This finding may lead to rethink treatment strategies, such as using older drugs or alternating periods of drug treatment with insulin injections.
A large cohort study found that sulfonylurea drugs increase the risk of mortality and cardiac events in patients with type 2 diabetes. The study suggests that sulfonylureas should be used only as a third-line treatment option, due to their potential to harm heart muscle.
Studies presented at the American Diabetes Association annual meeting showed ACTOS to be effective in reducing fasting insulin levels and improving A1C levels, with significant benefits seen when used alone or in combination with other oral antidiabetic medications.
ACTOS, an insulin sensitizer, is shown to improve diabetic dyslipidemia components when administered in combination with other diabetes therapies. The study found significant increases in average and peak LDL and HDL particle size, accompanied by a decrease in particle density.
Researchers discovered a direct link between sulfonylurea drugs and coronary arterial spasm, increasing blood pressure and heart damage. The study suggests that these common diabetes medications may pose an additional risk to diabetic patients already facing cardiovascular problems.